{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:49:23Z","timestamp":1787032163094,"version":"build-2736575974"},"reference-count":41,"publisher":"Becaris Publishing Limited","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:p>\n                    <jats:bold>Aim:<\/jats:bold>\n                    Recent network meta-analyses (NMAs) in metastatic castration-sensitive prostate cancer have not adequately addressed potential treatment effect modifiers and population imbalances, which introduces bias. Although, individual-patient data (IPD) are seldom available across all trials, recent methodological advances allow adjustments using a combination of IPD and aggregate data.\n                    <jats:bold>Materials &amp; methods:<\/jats:bold>\n                    IPD from the ARASENS trial (darolutamide\u00a0+\u00a0docetaxel\u00a0+\u00a0androgen-deprivation-therapy [ADT]) and aggregate data from a systematic review were analyzed. Two methods were used to adjust for population imbalances: multilevel network meta-regression (ML-NMR) using baseline characteristics, and network meta-interpolation (NMI) using subgroup data. Relative effects were estimated for an ARASENS-like population, with sensitivity analysis in an average trial population.\n                    <jats:bold>Results:<\/jats:bold>\n                    Twelve studies, including ARASENS, were included. All studies reported baseline characteristics for ML-NMR. Sufficient subgroup data for NMI were available in 8\/12 studies for overall survival (OS) and 5\/12 studies for progression-free survival (PFS). Darolutamide\u00a0+\u00a0docetaxel\u00a0+\u00a0ADT showed significant benefit over docetaxel\u00a0+\u00a0ADT, ADT and standard-nonsteroidal-antiandrogen\u00a0+\u00a0ADT in all analyses. ML-NMR showed improved OS for darolutamide\u00a0+\u00a0docetaxel\u00a0+\u00a0ADT compared with abiraterone\u00a0+\u00a0docetaxel\u00a0+\u00a0ADT, apalutamide\u00a0+\u00a0ADT, enzalutamide\u00a0+\u00a0ADT and abiraterone\u00a0+\u00a0ADT. ML-NMR also showed improved PFS for darolutamide\u00a0+\u00a0docetaxel\u00a0+\u00a0ADT compared with apalutamide\u00a0+\u00a0ADT and enzalutamide\u00a0+\u00a0ADT. Using NMI, darolutamide\u00a0+\u00a0docetaxel\u00a0+\u00a0ADT demonstrated OS benefit over abiraterone\u00a0+\u00a0ADT and PFS benefit relative to abiraterone\u00a0+\u00a0ADT and apalutamide\u00a0+\u00a0ADT. Findings were consistent in an average population, although ML-NMR did not show significant OS benefit of darolutamide\u00a0+\u00a0docetaxel\u00a0+\u00a0ADT over apalutamide\u00a0+\u00a0ADT.\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    Improved outcomes were observed with darolutamide\u00a0+\u00a0docetaxel\u00a0+\u00a0ADT compared with other therapies. By incorporating effect modifiers and addressing population imbalances, we provide clinicians with a more accurate understanding of treatment efficacy for better-informed decision-making.\n                  <\/jats:p>","DOI":"10.57264\/cer-2025-0100","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T12:38:51Z","timestamp":1767703131000},"source":"Crossref","is-referenced-by-count":1,"title":["Population-adjusted network meta-analyses provide new insights into the efficacy of treatment alternatives for metastatic castration-sensitive prostate cancer"],"prefix":"10.57264","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5767-0548","authenticated-orcid":false,"given":"Neal","family":"Shore","sequence":"first","affiliation":[{"name":"Carolina Urologic Research Center, Atlantic Urology Clinics, Myrtle Beach, SC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6563-4587","authenticated-orcid":false,"given":"Alicia K","family":"Morgans","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3438-4853","authenticated-orcid":false,"given":"Noman","family":"Paracha","sequence":"additional","affiliation":[{"name":"Bayer Pharmaceuticals, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8576-5552","authenticated-orcid":false,"given":"Howard","family":"Thom","sequence":"additional","affiliation":[{"name":"Clifton Insight, Bristol, UK"},{"name":"University of Bristol, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4763-8891","authenticated-orcid":false,"given":"Edna","family":"Keeney","sequence":"additional","affiliation":[{"name":"Clifton Insight, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1236-8529","authenticated-orcid":false,"given":"Philip","family":"Orishaba","sequence":"additional","affiliation":[{"name":"Clifton Insight, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2672-7841","authenticated-orcid":false,"given":"David","family":"Phillippo","sequence":"additional","affiliation":[{"name":"University of Bristol, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2967-5816","authenticated-orcid":false,"given":"David","family":"Aceituno","sequence":"additional","affiliation":[{"name":"Clifton Insight, Bristol, UK"},{"name":"Pontificia Universidad Cat\u00f3lica de Chile, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5990-4026","authenticated-orcid":false,"given":"Christopher JD","family":"Wallis","sequence":"additional","affiliation":[{"name":"Division of Urology, Department of Surgery, University of Toronto, Toronto, ON, Canada"},{"name":"Division of Urology, Department of Surgery, Mount Sinai Hospital, Toronto, ON, Canada"},{"name":"Department of Surgical Oncology, University Health Network, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6013-3276","authenticated-orcid":false,"given":"Elaine","family":"Gallagher","sequence":"additional","affiliation":[{"name":"Bayer Pharmaceuticals, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2569-4446","authenticated-orcid":false,"given":"Martin","family":"Boegemann","sequence":"additional","affiliation":[{"name":"University of Muenster Medical Center, Department of Urology, Muenster, Germany"},{"name":"West German Cancer Center, Muenster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"issue":"7","key":"e_1_3_8_3_2","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMra1701695","article-title":"Metastatic prostate cancer","volume":"378","author":"Sartor O","year":"2018","unstructured":"Sartor O, de Bono JS. Metastatic prostate cancer. N. Engl. J. Med. 378(7), 645\u2013657 (2018).","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"e_1_3_8_4_2","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney CJ","year":"2015","unstructured":"Sweeney CJ, Chen YH, Carducci M Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N. Engl. J. Med. 373(8), 737\u2013746 (2015).","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"e_1_3_8_5_2","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1093\/annonc\/mdy072","article-title":"Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol","volume":"29","author":"Sydes MR","year":"2018","unstructured":"Sydes MR, Spears MR, Mason MD Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Ann. Oncol. 29(5), 1235\u20131248 (2018).","journal-title":"Ann. Oncol."},{"issue":"4","key":"e_1_3_8_6_2","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi K","year":"2017","unstructured":"Fizazi K, Tran N, Fein L Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N. Engl. J. Med. 377(4), 352\u2013360 (2017).","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"e_1_3_8_7_2","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis ID","year":"2019","unstructured":"Davis ID, Martin AJ, Stockler MR Enzalutamide with standard first-line therapy in metastatic prostate cancer. N. Engl. J. Med. 381(2), 121\u2013131 (2019).","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"e_1_3_8_8_2","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1200\/JCO.22.00193","article-title":"Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer","volume":"40","author":"Armstrong AJ","year":"2022","unstructured":"Armstrong AJ, Azad AA, Iguchi T Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer. J. Clin. Oncol. 40(15), 1616\u20131622 (2022).","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"e_1_3_8_9_2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi KN","year":"2019","unstructured":"Chi KN, Agarwal N, Bjartell A Apalutamide for metastatic, castration-sensitive prostate cancer. N. Engl. J. Med. 381(1), 13\u201324 (2019).","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"e_1_3_8_10_2","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/ijc.34018","article-title":"Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476)","volume":"151","author":"James ND","year":"2022","unstructured":"James ND, Clarke NW, Cook A Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476). Int. J. Cancer 151(3), 422\u2013434 (2022).","journal-title":"Int. J. Cancer"},{"issue":"12","key":"e_1_3_8_11_2","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith MR","year":"2022","unstructured":"Smith MR, Hussain M, Saad F Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N. Engl. J. Med. 386(12), 1132\u20131142 (2022).","journal-title":"N. Engl. J. Med."},{"issue":"10336","key":"e_1_3_8_12_2","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, Phase III study with a 2 \u00d7 2 factorial design","volume":"399","author":"Fizazi K","year":"2022","unstructured":"Fizazi K, Foulon S, Carles J Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, Phase III study with a 2 \u00d7 2 factorial design. Lancet 399(10336), 1695\u20131707 (2022).","journal-title":"Lancet"},{"issue":"1","key":"e_1_3_8_13_2","article-title":"Darolutamide for metastatic hormone-sensitive prostate cancer: an overview of meta-analyses and indirect treatment comparisons","volume":"24","author":"Shore N","year":"2024","unstructured":"Shore N, Morgans AK, Paracha N Darolutamide for metastatic hormone-sensitive prostate cancer: an overview of meta-analyses and indirect treatment comparisons. Rev. Urol. 24(1), (2024). Available from: https:\/\/reviewsinurology.com\/issues\/vol\/24\/no\/1\/darolutamide-for-metastatic-hormone-sensitive-prostate-cancer-an-overview-of-meta-analyses-and-indirect-treatment-comparisons","journal-title":"Rev. Urol."},{"key":"e_1_3_8_14_2","volume-title":"NICE DSU Technical Support Document 2: A generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials","author":"Dias S","year":"2014","unstructured":"Dias S, Welton N, Sutton A, Ades A. NICE DSU Technical Support Document 2: A generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. NICE, UK (2014).Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK310366\/"},{"issue":"4","key":"e_1_3_8_15_2","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jval.2011.01.011","article-title":"Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on indirect treatment comparisons good research practices: part 2","volume":"14","author":"Hoaglin DC","year":"2011","unstructured":"Hoaglin DC, Hawkins N, Jansen JP Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on indirect treatment comparisons good research practices: part 2. Value Health 14(4), 429\u2013437 (2011).","journal-title":"Value Health"},{"issue":"4","key":"e_1_3_8_16_2","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.jval.2011.04.002","article-title":"Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on indirect treatment comparisons good research practices: part 1","volume":"14","author":"Jansen JP","year":"2011","unstructured":"Jansen JP, Fleurence R, Devine B Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on indirect treatment comparisons good research practices: part 1. Value Health 14(4), 417\u2013428 (2011).","journal-title":"Value Health"},{"issue":"10","key":"e_1_3_8_17_2","doi-asserted-by":"crossref","first-page":"782","DOI":"10.2471\/BLT.16.174326","article-title":"Use of network meta-analysis in clinical guidelines","volume":"94","author":"Kanters S","year":"2016","unstructured":"Kanters S, Ford N, Druyts E Use of network meta-analysis in clinical guidelines. Bull. World Health Organ. 94(10), 782\u2013784 (2016).","journal-title":"Bull. World Health Organ."},{"key":"e_1_3_8_18_2","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions, Version 6.5","author":"Chaimani A","year":"2024","unstructured":"Chaimani A, Caldwell DM, Li T, Higgins JP, Salanti G. Chapter 11: undertaking network meta-analyses [last updated October 2019]. In: Higgins JP, Thomas J, Chandler Jet al. (Eds). Cochrane Handbook for Systematic Reviews of Interventions, Version 6.5. Cochrane (2024). Available from: https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/current\/chapter-11"},{"issue":"5","key":"e_1_3_8_19_2","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/jrsm.1700","article-title":"Twenty years of network meta-analysis: continuing controversies and recent developments","volume":"15","author":"Ades AE","year":"2024","unstructured":"Ades AE, Welton NJ, Dias S, Phillippo DM, Caldwell DM. Twenty years of network meta-analysis: continuing controversies and recent developments. Res. Synth. Methods 15(5), 702\u2013727 (2024).","journal-title":"Res. Synth. Methods"},{"issue":"7","key":"e_1_3_8_20_2","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/S1470-2045(23)00230-9","article-title":"Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: aa systematic review and meta-analysis of individual participant data from randomised trials","volume":"24","author":"Vale CL","year":"2023","unstructured":"Vale CL, Fisher DJ, Godolphin PJ Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: aa systematic review and meta-analysis of individual participant data from randomised trials. Lancet Oncol. 24(7), 783\u2013797 (2023).","journal-title":"Lancet Oncol."},{"issue":"3","key":"e_1_3_8_21_2","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1111\/rssa.12579","article-title":"Multilevel network meta-regression for population-adjusted treatment comparisons","volume":"183","author":"Phillippo DM","year":"2020","unstructured":"Phillippo DM, Dias S, Ades AE Multilevel network meta-regression for population-adjusted treatment comparisons. J. R. Stat. Soc. Ser. A Stat. Soc. 183(3), 1189\u20131210 (2020).","journal-title":"J. R. Stat. Soc. Ser. A Stat. Soc."},{"issue":"5","key":"e_1_3_8_22_2","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1177\/0272989X13485157","article-title":"Evidence synthesis for decision making 3: heterogeneity \u2013 subgroups, meta-regression, bias, and bias-adjustment","volume":"33","author":"Dias S","year":"2013","unstructured":"Dias S, Sutton AJ, Welton NJ, Ades AE. Evidence synthesis for decision making 3: heterogeneity \u2013 subgroups, meta-regression, bias, and bias-adjustment. Med. Decis. Making 33(5), 618\u2013640 (2013).","journal-title":"Med. Decis. Making"},{"issue":"19","key":"e_1_3_8_23_2","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1080\/14796694.2025.2526324","article-title":"Matching-adjusted indirect comparison of enzalutamide versus darolutamide doublet in MHSPC","volume":"21","author":"Armstrong AJ","year":"2025","unstructured":"Armstrong AJ, Pandya BJ, Bhadauria HS Matching-adjusted indirect comparison of enzalutamide versus darolutamide doublet in MHSPC. Future Oncol. 21(19), 2459\u20132469 (2025).","journal-title":"Future Oncol."},{"issue":"2","key":"e_1_3_8_24_2","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/jrsm.1608","article-title":"Network meta-interpolation: effect modification adjustment in network meta-analysis using subgroup analyses","volume":"14","author":"Harari O","year":"2023","unstructured":"Harari O, Soltanifar M, Cappelleri JC Network meta-interpolation: effect modification adjustment in network meta-analysis using subgroup analyses. Res. Synth. Methods 14(2), 211\u2013233 (2023).","journal-title":"Res. Synth. Methods"},{"key":"e_1_3_8_25_2","unstructured":"Welton NJ Phillippo DM Owen R CHTE2020 sources and synthesis of evidence; update to evidence synthesis methods. (2020). Available from: https:\/\/sheffield.ac.uk\/nice-dsu\/methods-development\/chte2020-sources-and-synthesis-evidence"},{"key":"e_1_3_8_26_2","unstructured":"Directorate-General for Health and Food Safety. Methodological guideline for quantitative evidence synthesis: direct and indirect comparisons (2024). Available from: https:\/\/health.ec.europa.eu\/latest-updates\/methodological-guideline-quantitative-evidence-synthesis-direct-and-indirect-comparisons-2024-03-25_en"},{"key":"e_1_3_8_27_2","doi-asserted-by":"crossref","first-page":"e070849","DOI":"10.1136\/bmj-2022-070849","article-title":"Reporting guideline for overviews of reviews of healthcare interventions: development of the prior statement","volume":"378","author":"Gates M","year":"2022","unstructured":"Gates M, Gates A, Pieper D Reporting guideline for overviews of reviews of healthcare interventions: development of the prior statement. BMJ 378, e070849 (2022).","journal-title":"BMJ"},{"key":"e_1_3_8_28_2","doi-asserted-by":"crossref","first-page":"105906","DOI":"10.1016\/j.ijsu.2021.105906","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"88","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int. J. Surg. 88, 105906 (2021).","journal-title":"Int. J. Surg."},{"key":"e_1_3_8_29_2","volume-title":"NICE DSU Technical Support Document 18: Methods for population-adjusted indirect comparisons in submission to NICE","author":"Phillippo D","year":"2016","unstructured":"Phillippo D, Ades A, Dias S NICE DSU Technical Support Document 18: Methods for population-adjusted indirect comparisons in submission to NICE. NICE, UK (2016)."},{"issue":"6","key":"e_1_3_8_30_2","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.euo.2022.04.007","article-title":"Treatments for metastatic hormone-sensitive prostate cancer: systematic review, network meta-analysis, and benefit\u2013harm assessment","volume":"5","author":"Menges D","year":"2022","unstructured":"Menges D, Yebyo HG, Sivec-Muniz S Treatments for metastatic hormone-sensitive prostate cancer: systematic review, network meta-analysis, and benefit\u2013harm assessment. Eur. Urol. Oncol. 5(6), 605\u2013616 (2022).","journal-title":"Eur. Urol. Oncol."},{"issue":"6","key":"e_1_3_8_31_2","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.eururo.2022.08.002","article-title":"Androgen receptor signaling inhibitors in addition to docetaxel with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis","volume":"82","author":"Yanagisawa T","year":"2022","unstructured":"Yanagisawa T, Rajwa P, Thibault C Androgen receptor signaling inhibitors in addition to docetaxel with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis. Eur. Urol. 82(6), 584\u2013598 (2022).","journal-title":"Eur. Urol."},{"key":"e_1_3_8_32_2","volume-title":"Texts in statistical science","author":"Lunn D","year":"2013","unstructured":"Lunn D, Jackson C, Best N, Thomas A, Spiegelhalter DJ. The Bugs Book: a practical introduction to Bayesian analysis. Texts in statistical science. CRC Press (2013)."},{"key":"e_1_3_8_33_2","unstructured":"The R Project for statistical computing. Available from: https:\/\/www.r-project.org\/"},{"key":"e_1_3_8_34_2","unstructured":"Phillippo DM. multinma: Bayesian network meta-analysis of individual and aggregate data (2025). Available from: https:\/\/research-information.bris.ac.uk\/en\/publications\/multinma-bayesian-network-meta-analysis-of-individual-and-aggrega\/"},{"issue":"16","key":"e_1_3_8_35_2","doi-asserted-by":"crossref","first-page":"5081","DOI":"10.1200\/JCO.2022.40.16_suppl.5081","article-title":"Eight-year survival rates by baseline prognostic groups in patients with metastatic hormone-sensitive prostate cancer (mHSPC): an analysis from the ECOG-ACRIN 3805 (CHAARTED) trial","volume":"40","author":"Tripathi A","year":"2022","unstructured":"Tripathi A, Chen Y-H, Jarrard DF Eight-year survival rates by baseline prognostic groups in patients with metastatic hormone-sensitive prostate cancer (mHSPC): an analysis from the ECOG-ACRIN 3805 (CHAARTED) trial. J. Clin. Oncol. 40(Suppl. 16), 5081\u20135081 (2022).","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"e_1_3_8_36_2","doi-asserted-by":"crossref","first-page":"e2034633","DOI":"10.1001\/jamanetworkopen.2020.34633","article-title":"Clinical efficacy of enzalutamide vs bicalutamide combined with androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: a randomized clinical trial","volume":"4","author":"Vaishampayan UN","year":"2021","unstructured":"Vaishampayan UN, Heilbrun LK, Monk P 3rd Clinical efficacy of enzalutamide vs bicalutamide combined with androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: a randomized clinical trial. JAMA Netw. Open 4(1), e2034633 (2021).","journal-title":"JAMA Netw. Open"},{"issue":"2","key":"e_1_3_8_37_2","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.eururo.2015.11.005","article-title":"Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized Phase III GETUG-AFU15 trial","volume":"70","author":"Gravis G","year":"2016","unstructured":"Gravis G, Boher JM, Joly F Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized Phase III GETUG-AFU15 trial. Eur. Urol. 70(2), 256\u2013262 (2016).","journal-title":"Eur. Urol."},{"issue":"10024","key":"e_1_3_8_38_2","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James ND","year":"2016","unstructured":"James ND, Sydes MR, Clarke NW Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 387(10024), 1163\u20131177 (2016).","journal-title":"Lancet"},{"issue":"1","key":"e_1_3_8_39_2","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1177\/0272989X221117162","article-title":"Validating the assumptions of population adjustment: application of multilevel network meta-regression to a network of treatments for plaque psoriasis","volume":"43","author":"Phillippo DM","year":"2023","unstructured":"Phillippo DM, Dias S, Ades AE Validating the assumptions of population adjustment: application of multilevel network meta-regression to a network of treatments for plaque psoriasis. Med. Decis. Making 43(1), 53\u201367 (2023).","journal-title":"Med. Decis. Making"},{"issue":"36","key":"e_1_3_8_40_2","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.1200\/JCO-24-01798","article-title":"Darolutamide in combination with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the Phase III ARANOTE trial","volume":"42","author":"Saad F","year":"2024","unstructured":"Saad F, Vjaters E, Shore N Darolutamide in combination with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the Phase III ARANOTE trial. J. Clin. Oncol. 42(36), 4271\u20134281 (2024).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_8_41_2","unstructured":"NICE. Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer. TA903 (2023). Available from: https:\/\/www.nice.org.uk\/guidance\/ta903"},{"key":"e_1_3_8_42_2","unstructured":"NICE. Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer. TA741 (2021). Available from: https:\/\/www.nice.org.uk\/guidance\/ta741"},{"issue":"1","key":"e_1_3_8_43_2","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1186\/s13643-022-02137-6","article-title":"Duplicated network meta-analysis in advanced prostate cancer: a case study and recommendations for change","volume":"11","author":"Fisher DJ","year":"2022","unstructured":"Fisher DJ, Burdett S, Vale C, White IR, Tierney JF. Duplicated network meta-analysis in advanced prostate cancer: a case study and recommendations for change. Syst. Rev. 11(1), 274 (2022).","journal-title":"Syst. Rev."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2025-0100","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T10:15:19Z","timestamp":1770286519000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2025-0100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.57264\/cer-2025-0100"],"URL":"https:\/\/doi.org\/10.57264\/cer-2025-0100","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"article-number":"e250100"}}